FDA Signals New Testosterone Pathway - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

  • By

  • Kathryn Wighton

  • April 16, 2026

  • 2 min

Share

  • 1

    The FDA is encouraging sponsors of testosterone replacement therapy to pursue a new indication for low libido in men with idiopathic hypogonadism.

  • 2

    Currently, TRT products are approved only for men with hypogonadism due to established structural or genetic causes.

  • 3

    The FDA's review indicated that TRT may be safe and effective for men with decreased libido linked to idiopathic hypogonadism.

  • 4

    Sponsors are advised to contact the FDA by April 30 to discuss submission requirements for supplemental applications.

  • 5

    Any new indication approval will require substantial evidence of effectiveness and a favorable risk-benefit assessment.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Menstrual Fluid May Aid in Endometriosis Detection

Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.